# Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)

> **NCT02488993** · — · COMPLETED · sponsor: **Norgine** · enrollment: 389 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **OTHER:** Prospective Phase Rifaximin-α 550mg
- **OTHER:** Prospective Phase No Rifaximin-α 550mg
- **OTHER:** Retrospective Phase

## Key facts

- **NCT ID:** NCT02488993
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-09-29
- **Final completion:** 2018-09-29
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2018-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02488993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02488993, "Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02488993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*